InterCure enters LOI for business partnership with Tyson 2.0

InterCure announced that they have entered into a binding letter of intent for a business partnership. The partnership will see InterCure, a leading expert in pharmaceutical grade medical cannabis, granted an exclusive distribution license to cultivate, manufacture, sell, market, and distribute all approved products and brands of TYSON 2.0 in Israel, Australia, United Kingdom, Germany and other EU countries such as Switzerland. InterCure will also have the right to use the name, the marks and the TYSON 2.0 intellectual property in these territories. The partnership also includes a license for InterCure to use TYSON 2.0’s intellectual property and genetics for cultivation and production of products.